272 related articles for article (PubMed ID: 33798711)
1. Dual Biologic or Small Molecule Therapy for Treatment of Inflammatory Bowel Disease: A Systematic Review and Meta-analysis.
Ahmed W; Galati J; Kumar A; Christos PJ; Longman R; Lukin DJ; Scherl E; Battat R
Clin Gastroenterol Hepatol; 2022 Mar; 20(3):e361-e379. PubMed ID: 33798711
[TBL] [Abstract][Full Text] [Related]
2. Dual Biologic or Small Molecule Therapy in Refractory Pediatric Inflammatory Bowel Disease (DOUBLE-PIBD): A Multicenter Study from the Pediatric IBD Porto Group of ESPGHAN.
Yerushalmy-Feler A; Olbjorn C; Kolho KL; Aloi M; Musto F; Martin-de-Carpi J; Lozano-Ruf A; Yogev D; Matar M; Scarallo L; Bramuzzo M; de Ridder L; Kang B; Norden C; Wilson DC; Tzivinikos C; Turner D; Cohen S
Inflamm Bowel Dis; 2024 Feb; 30(2):159-166. PubMed ID: 37042978
[TBL] [Abstract][Full Text] [Related]
3. Dual Biologic and Small Molecule Therapy for the Treatment of Refractory Pediatric Inflammatory Bowel Disease.
Dolinger MT; Spencer EA; Lai J; Dunkin D; Dubinsky MC
Inflamm Bowel Dis; 2021 Jul; 27(8):1210-1214. PubMed ID: 33125058
[TBL] [Abstract][Full Text] [Related]
4. Comparative Risk of Serious Infections With Biologic Agents and Oral Small Molecules in Inflammatory Bowel Diseases: A Systematic Review and Meta-Analysis.
Solitano V; Facciorusso A; Jess T; Ma C; Hassan C; Repici A; Jairath V; Armuzzi A; Singh S
Clin Gastroenterol Hepatol; 2023 Apr; 21(4):907-921.e2. PubMed ID: 35944832
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of simultaneous treatment with two biologic medications in refractory Crohn's disease.
Yang E; Panaccione N; Whitmire N; Dulai PS; Vande Casteele N; Singh S; Boland BS; Collins A; Sandborn WJ; Panaccione R; Battat R
Aliment Pharmacol Ther; 2020 Jun; 51(11):1031-1038. PubMed ID: 32329532
[TBL] [Abstract][Full Text] [Related]
6. Effect of Obesity on Risk of Hospitalization, Surgery, and Serious Infection in Biologic-Treated Patients With Inflammatory Bowel Diseases: A CA-IBD Cohort Study.
Gu P; Luo J; Kim J; Paul P; Limketkai B; Sauk JS; Park S; Parekh N; Zheng K; Rudrapatna V; Syal G; Ha C; McGovern DP; Melmed GY; Fleshner P; Eisenstein S; Ramamoorthy S; Dulai PS; Boland BS; Grunvald E; Mahadevan U; Ohno-Machado L; Sandborn WJ; Singh S
Am J Gastroenterol; 2022 Oct; 117(10):1639-1647. PubMed ID: 35973139
[TBL] [Abstract][Full Text] [Related]
7. Impact of biologic therapies and small molecules on the risk of major adverse cardiovascular events in patients with inflammatory bowel diseases: systematic review and meta-analysis of randomized controlled trials.
Shehab M; Alrashed F; Alkazemi A; Lakatos PL; Bessissow T
Expert Rev Gastroenterol Hepatol; 2023 May; 17(5):469-477. PubMed ID: 36961082
[TBL] [Abstract][Full Text] [Related]
8. Dual-Targeted Therapy in Pediatric Inflammatory Bowel Disease: A Comprehensive Review.
Yerushalmy-Feler A; Brauner C; Cohen S
Paediatr Drugs; 2023 Sep; 25(5):489-498. PubMed ID: 37318737
[TBL] [Abstract][Full Text] [Related]
9. Comparative Safety and Effectiveness of Biologic Therapy for Crohn's Disease: A CA-IBD Cohort Study.
Singh S; Kim J; Luo J; Paul P; Rudrapatna V; Park S; Zheng K; Syal G; Ha C; Fleshner P; McGovern D; Sauk JS; Limketkai B; Dulai PS; Boland BS; Eisenstein S; Ramamoorthy S; Melmed G; Mahadevan U; Sandborn WJ; Ohno-Machado L
Clin Gastroenterol Hepatol; 2023 Aug; 21(9):2359-2369.e5. PubMed ID: 36343846
[TBL] [Abstract][Full Text] [Related]
10. Safety of Biologic and Small Molecule Therapy for Inflammatory Bowel Disease Among Solid Organ Transplant Recipients: Systematic Review and Meta-Analysis.
Taneja V; Anand RS; El-Dallal M; Dong J; Desai N; Taneja I; Feuerstein JD
Inflamm Bowel Dis; 2024 Apr; 30(4):585-593. PubMed ID: 37300512
[TBL] [Abstract][Full Text] [Related]
11. Anti-IL-12/23p40 antibodies for maintenance of remission in Crohn's disease.
Davies SC; Nguyen TM; Parker CE; MacDonald JK; Jairath V; Khanna R
Cochrane Database Syst Rev; 2019 Dec; 12(12):CD012804. PubMed ID: 31828765
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and Safety of Dual Targeted Therapy for Partially or Non-responsive Inflammatory Bowel Disease: A Systematic Review of the Literature.
Berinstein EM; Sheehan JL; Jacob J; Steiner CA; Stidham RW; Shannon C; Bishu S; Levine J; Cohen-Mekelburg SA; Waljee AK; Higgins PDR; Berinstein JA
Dig Dis Sci; 2023 Jun; 68(6):2604-2623. PubMed ID: 36807832
[TBL] [Abstract][Full Text] [Related]
13. Role of the combination of biologics and/or small molecules in the treatment of patients with inflammatory bowel disease.
Balderramo D
World J Gastroenterol; 2022 Dec; 28(47):6743-6751. PubMed ID: 36620336
[TBL] [Abstract][Full Text] [Related]
14. Effectiveness and Safety of Ustekinumab for Pediatric Inflammatory Bowel Disease: A Systematic Review.
Fang S; Zhang S; Zhang C; Wang L
Paediatr Drugs; 2023 Sep; 25(5):499-513. PubMed ID: 37528211
[TBL] [Abstract][Full Text] [Related]
15. Comparative Risk of Serious Infections With Biologic and/or Immunosuppressive Therapy in Patients With Inflammatory Bowel Diseases: A Systematic Review and Meta-Analysis.
Singh S; Facciorusso A; Dulai PS; Jairath V; Sandborn WJ
Clin Gastroenterol Hepatol; 2020 Jan; 18(1):69-81.e3. PubMed ID: 30876964
[TBL] [Abstract][Full Text] [Related]
16. Anti-IL-12/23p40 antibodies for induction of remission in Crohn's disease.
MacDonald JK; Nguyen TM; Khanna R; Timmer A
Cochrane Database Syst Rev; 2016 Nov; 11(11):CD007572. PubMed ID: 27885650
[TBL] [Abstract][Full Text] [Related]
17. No Benefit of Concomitant Immunomodulator Therapy on Efficacy of Biologics That Are Not Tumor Necrosis Factor Antagonists in Patients With Inflammatory Bowel Diseases: A Meta-analysis.
Yzet C; Diouf M; Singh S; Brazier F; Turpin J; Nguyen-Khac E; Meynier J; Fumery M
Clin Gastroenterol Hepatol; 2021 Apr; 19(4):668-679.e8. PubMed ID: 32629124
[TBL] [Abstract][Full Text] [Related]
18. Methotrexate for induction of remission in refractory Crohn's disease.
McDonald JW; Tsoulis DJ; Macdonald JK; Feagan BG
Cochrane Database Syst Rev; 2012 Dec; 12():CD003459. PubMed ID: 23235598
[TBL] [Abstract][Full Text] [Related]
19. Dual biological therapy with anti-TNF, vedolizumab or ustekinumab in inflammatory bowel disease: a systematic review with pool analysis.
Ribaldone DG; Pellicano R; Vernero M; Caviglia GP; Saracco GM; Morino M; Astegiano M
Scand J Gastroenterol; 2019 Apr; 54(4):407-413. PubMed ID: 30945576
[No Abstract] [Full Text] [Related]
20. Combining biological therapies in patients with inflammatory bowel disease: a Finnish multi-centre study.
Eronen H; Kolehmainen S; Koffert J; Koskinen I; Oksanen P; Jussila A; Huhtala H; Sipponen T; Ilus T
Scand J Gastroenterol; 2022 Aug; 57(8):936-941. PubMed ID: 35238727
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]